Hutchmed (china) Limited (HCM) Share Price & Analysis

Open: 167.50
High: 168.80
Low: 167.50
Close: 168.80
Change: +5.00 (3.03%)
Volume: 720

Dr. Dan ELDARChairman and Non-executive Director

–

Mr. Johnny CHENGExecutive Director, Acting Chief Executive Officer and Chief Financial Officer

–

Dr. Weiguo SUExecutive Director, Chief Executive Officer and Chief Scientific Officer

–

Ms. Edith SHIHNon-executive Director and Company Secretary

–

Mr. WONG Tak Wai

–

HUTCHMED is a biopharmaceutical company that focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases on a global scale. They are dedicated to innovation and commercialization in the field of biopharmaceuticals.

Industry: Health Care
Sector: Health Care
LEI: 2138006X34YDQ6OBYE79
Region: North America
Admission date: 19 May 2006
Website: www.hutch-med.com
X: @hutchmed

Shares in issue: 872,327,620
Total Voting Rights: 872,327,620

Last updated:

Open: 167.50
High: 168.80
Low: 167.50
Close: 168.80
Change: +5.00 (3.03%)
Volume: 720

Dr. Dan ELDARChairman and Non-executive Director

–

Mr. Johnny CHENGExecutive Director, Acting Chief Executive Officer and Chief Financial Officer

–

Dr. Weiguo SUExecutive Director, Chief Executive Officer and Chief Scientific Officer

–

Ms. Edith SHIHNon-executive Director and Company Secretary

–

Mr. WONG Tak Wai

–

Industry: Health Care
Sector: Health Care
LEI: 2138006X34YDQ6OBYE79
Region: North America
Admission date: 19 May 2006
Website: www.hutch-med.com
X: @hutchmed

Shares in issue: 872,327,620
Total Voting Rights: 872,327,620

Last updated:

ISIN: KYG4672N1198
Exchange: AIMX
Market: Aim
Market Segment: AMSM
Market Sector: ASM6

ISIN: KYG4672N1198
Exchange: AIMX
Market: Aim
Market Segment: AMSM
Market Sector: ASM6

2 Jul 2026	09:30:00	HUTCHMED Announces NMPA Approval for ORPATHYS
30 Jun 2026	09:30:00	HUTCHMED to Announce 2026 Half-Year Results
29 Jun 2026	09:30:00	Announcement on blocklisting six monthly return
25 Jun 2026	07:00:08	HUTCHMED Highlights Phase II Data at ESMO

2 Jul 2026	09:30:00	HUTCHMED Announces NMPA Approval for ORPATHYS
30 Jun 2026	09:30:00	HUTCHMED to Announce 2026 Half-Year Results
29 Jun 2026	09:30:00	Announcement on blocklisting six monthly return
25 Jun 2026	07:00:08	HUTCHMED Highlights Phase II Data at ESMO

Hutchmed (china) Limited

Hutchmed (china) Limited

Price Chart

Recent RNS announcements

Directors (10)

In the Press

Company details

Shares details